



Company Overview

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma's headquarters are in Boulder, Colorado, with manufacturing operations in Jalisco, Mexico. European marketing and sales are headquartered in Roermond, Netherlands.

National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

Nov 13 2025, 8:30 AM EST

Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf

Nov 6 2025, 4:01 PM EST

Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results

Nov 4 2025, 8:56 AM EST

Stock Overview

| | |
|------------|-------------------|
| Symbol | SNOA |
| Exchange | Nasdaq |
| Market Cap | 5.83m |
| Last Price | \$3.43 |
| 52-Week | \$1.75 - \$6.9199 |

01/12/2026 09:00 PM EST

Investor Relations

T: 470-938-1011
ir@sonomapharma.com

Management Team

Amy Trombly

Chief Executive Officer

Jerry Dvonch

Chief Financial Officer

Sonoma Pharmaceuticals, Inc.

5445 Conestoga Court
Suite 150
Boulder, CO 80301

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.